The technology developed by Atonco is a highly promising disruptive innovation in the eradication of residual microscopic disease or isolated or clustered residual tumor cells, rapidly accessible to an astatine-211 labeled radiopharmaceutical.

The use of alpha-emitting radionuclides is a topical issue and of great medical interest because of the high cytotoxic double stranded DNA break effect of alpha particles on tumor cells due to their high linear energy transfer (LET) and of the recognized good tolerance due to the very short path length of alpha particle allowing to relatively spare normal tissue cells close to tumor cell clusters.